Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sarepta Therapeutics; Sarepta Therapeutics, Inc.
• Collaborator: United States Department of Defense

Criteria

Inclusion Criteria:

• Male or female and between the ages of 18 and 50 years in good general health

• Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential

• Volunteers must be willing to undergo a urine screen for drugs of abuse

Exclusion Criteria:

• Pregnancy or breastfeeding.

• Any clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis

• Positive test for human immunodeficiency virus, hepatitis B or hepatitis C or known history of HIV infection